Sumita Ray Email Address

Principal

Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Calithera’s lead product candidate, CB-839, is currently being evaluated in three Phase 1 clinical trials in solid and hematological cancers. CB-1158 is a first-in- class immuno-oncology metabolic checkpoint inhibitor targeting arginase, a critical immunosuppressive enzyme responsible for T-cell suppression by myeloid-derived suppressor cells. Arginase depletes arginine, a nutrient that is critical for the activation, growth and survival of the body’s cancer-fighting immune cells, known as cytotoxic T -cells. Calithera is headquartered in South San Francisco, California.

Seasoned C-Level Executive and Member of Executive Committee, reporting to CEO and Board of Directors; Global Regulatory, Compliance, Fraud & Abuse Attorney with 16+ years of Pharmaceutical/BioTechnology experience both in private practice and in-house legal departments, including experience Building, Leading and Managing In-House Legal and Compliance Departments Specialties: FDA Regulatory Law, Global Health Care Law, Brand Support (Primary Care, Oncology and Neurology), Product Launches, Collaborations and Alliances, Global Fraud & Abuse and Compliance, Product Liability, Pharmaceutical Litigation, OIG Corporate Integrity Agreement Negotiation & Implementation, Building/Leading & Managing Legal and Compliance Teams